A- A A+

Ming-Huang Chen (陳明晃)

  • 2875-7270
Ming-Huang Chen(陳明晃)

簡介

學歷
  1. 國立陽明大學 臨床醫學研究所 博士
  2. 中國醫學大學 醫學系 醫學士
經歷 現職:
  1. 2021- 迄今 國立陽明交通大學 醫學系 內科學科 教授
  2. 2020- 迄今 臺北榮民總醫院 腫瘤醫學部 腫瘤免疫治療中心 中心主任
  3. - 迄今 臺北榮民總醫院 腫瘤醫學部 藥物治療科 主治醫師
經歷:
  1. - 2021 國立陽明大學 醫學系 內科學科 副教授
  2. - 國立陽明大學 醫學系 內科學科 助理教授
  3. - 國立陽明大學 醫學系 內科學科 講師
  4. - 臺北榮民總醫院 內科部 血液腫瘤科 主治醫師
  5. - 臺北榮民總醫院 內科部 腫瘤科 住院總醫師
醫療專長
  1. 腫瘤內科、腸胃道腫瘤(食道癌、胃癌、大腸直腸癌、膽管及胰臟癌)及神經內分泌腫瘤診斷及治療、臨床試驗發起及執行
證照
  1. 內科專科醫師、腫瘤內科專科醫師、血液病科專科醫師、癌症安寧緩和醫療專科醫師、血液及骨髓移植專科醫師

著作

PubMed

  1. Chen MH, Weng JJ, Cheng CT, Wu RC, Huang SC, Wu CE, Chung YH, Liu CY, Chang MH, Chen MH, Chiang KC, Yeh TS, Su Y*, Yeh CN*.  ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients. Clin Cancer Res 2016 Aug; 22(16): 4225-35. (IF: 8.738; Oncology 12/213)

  2. Yeh CN, Chang YC, Su Y, Shin-Shian Hsu D, Cheng CT, Wu RC, Chung YH, Chiang KC, Yeh TS, Lu ML, Liu CY, Mu-Hsin Chang P, Chen MH, Huang CF, Hsiao M*, Chen MH*.  Identification of MALT1 as Both a Prognostic Factor and a Potential Therapeutic Target of Regorafenib in Cholangiocarcinoma Patients. Oncotarget 2017 Dec; 8(69): 113444-59. (IF: 5.168; Oncology 44/217; Cell Biology 48/189)

  3. Chen MH, Yen CC, Cheng CT, Wu RC, Huang SC, Yu CS, Chung YH, Liu CY, Chang PM, Chao Y, Chen MH, Chen YF, Chiang KC, Yeh TS, Chen TC, Huang CY, Yeh CN.  Identification of SPHK1 as a Therapeutic Target and Marker of Poor Prognosis in Cholangiocarcinoma. Oncotarget 2015 Sep; 6(27): 23594-608. (IF: 5.008; Oncology 36/213; Cell Biology 43/187)

  4. Chou WC, Lin PH, Yeh YC, Shyr YM, Fang WL, Wang SE, Liu CY, Chang PM, Chen MH, Hung YP, Li CP, Chao Y*, Chen MH*.  Genes Involved in Angiogenesis and mTOR Pathways Are Frequently Mutated in Asian Patients with Pancreatic Neuroendocrine Tumors. Int J Biol Sci 2016 Nov; 12(12): 1523-32. (IF: 3.982; Biochemistry & Molecular Biology 78/289)

  5. Cheng CT, Chen YY, Wu RC, Tsai CY, Chiang KC, Yeh TS, Chen MH*, Yeh CN*.  MET RON Dual Inhibitor, BMS 777607, Suppresses Cholangiocarcinoma Cell Growth, and MET RON Upregulation Indicates Worse Prognosis for Intra Hepatic Cholangiocarcinoma Patients. Oncol Rep 2018 Sep; 40(3): 1411-21. Epub 2018 Jul. (IF: 2.976; Oncology 123/222)

  6. Chen MH, Lin J, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP*, Chao Y*.  A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed By Docetaxel Plus Capecitabine in Patients with Unresectable Gastric Adenocarcinoma: the TCOG 3211 Clinical Trial. Medicine (Baltimore) 2016 Jan; 95(3): e2565. (IF: 2.133; Medicine, General & Internal 40/155)

  7. Lin LY, Yeh YC, Chu CH, Won JGS, Shyr YM, Chao Y, Li CP, Wang SE, Chen MH*.  Endocan Expression is Correlated with Poor Progression-Free Survival in Patients with Pancreatic Neuroendocrine Tumors. Medicine (Baltimore) 2017 Oct; 96(41): e8262. (IF: 1.803; Medicine, General & Internal 58/154)

  8. Chang PM, Cheng CT, Wu RC, Chung YH, Chiang KC, Yeh TS, Liu CY, Chen MH, Chen MH*, Yeh CN*.  Nab-Paclitaxel is Effective against Intrahepatic Cholangiocarcinoma via Disruption of Desmoplastic Stroma. Oncol Lett 2018 Jul; 16(1): 566-72. Epub 2018 May. (IF: 1.664; Oncology 193/222)

  9. Chen MH, Kuo YJ, Yeh YC, Lin YC, Tzeng CH, Liu CY, Chang PM, Chen MH, Jeng YM, Chao Y*.  High Neuroendocrine Component is a Factor for Poor Prognosis in Gastrointestinal High-Grade Malignant Mixed Adenoneuroendocrine Neoplasms. J Chin Med Assoc 2015 Aug; 78(8): 454-9. Epub 2015 May. (IF: 1.013; Medicine, General & Internal 88/155)